FOI.ICB-2526/157: Bevacizumab Gamma (Lytenava®) for Neovascular (wet) Age-related Macular Degeneration (NICE TA1022) FOI.ICB-2526/157: Bevacizumab Gamma (Lytenava®) for Neovascular (wet) Age-related Macular Degeneration (NICE TA1022) Filename: FOI.ICB-2526_157-BEVACIZUMAB-GAMMA-FINAL-RESPONSE.PDF File type: PDF File size: 289 KB Download